Early Cancer Detection across the Translational Pipeline

with-in-sight 12/9/2026: early cancer detection across the translational pipeline

Wednesday, December 9, 2026

Virtual event (Zoom)

Register via Eventbrite

Join us online for a journey from lab bench to patient bedside. Koch Institute faculty and alumni will explore three projects in early cancer detection at the fundamental research, translational, and clinical stages.

Featuring

Pre-clinical pancreatic cancer advances

Matthew Vander Heiden

Director, MIT Koch Institute

Lester Wolfe (1919) Professor of Molecular Biology

New startup Amplifyer Bio developing liquid biopsy approaches

Sangeeta Bhatia

John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science

Christopher Love

Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering

CisionVision’s imaging tools already in the clinic

Jeremy Li

CEO and co-founder of CisionVision

Belcher Lab postdoc alum

Related News

The mechanisms of metastasis

Knowable Magazine

Knowable Magazine offers an accessible, in-depth look at metastasis and cancer metabolism, featuring KI director Matthew Vander Heiden. 

Better blood tests for cancer

MIT News

A collaboration between Sangeeta Bhatia, Chris Love, and their Broad Institute colleague Viktor Adalsteinsson could improve the sensitivity of liquid biopsies used to detect, monitor, and guide treatment of tumors.

MIT’s Tiny Technologies Go to Washington

MIT Koch Institute

A team from the Marble Center for Cancer Nanomedicine showed a Washington D.C. audience several examples of how nanotechnologies developed at the Koch Institute can transform the detection and treatment of cancer and other diseases.

There's no place like home

MIT Koch Institute

Vander Heiden Lab researchers showed that metastasized cancer cells prefer the nutrient landscape of their home tissue and retain more of their metabolic programming than previously thought.